Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (37)

« Back to Publications

ntiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)

Jittamala P. et al, (2025), eClinicalMedicine, 80, 103036 - 103036

Evidence that remdesivir treatment reduces viral titers in patients with COVID-19

Boyd S. et al, (2024), Antimicrobial Agents and Chemotherapy, 68

Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial

Schilling WHK. et al, (2024), PLOS Medicine, 21, e1004428 - e1004428

Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)

Wongnak P. et al, (2024), The Lancet Infectious Diseases, 24, 953 - 963

Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study

Perrone C. et al, (2024)

ntiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)

Jittamala P. et al, (2024)

Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)

Wongnak P. et al, (2024)

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial

Luvira V. et al, (2024), BMC Infectious Diseases, 24

ntiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

Schilling WHK. et al, (2024), The Lancet Infectious Diseases, 24, 36 - 45

Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)

Jittamala P. et al, (2023), The Journal of Infectious Diseases, 228, 1318 - 1325

Reflections on Participation in a Trial on Hydroxychloroquine as Prevention for COVID-19 among Health Workers in Niger

Kabore Y. et al, (2023), The American Journal of Tropical Medicine and Hygiene, 109, 511 - 514

Raising awareness of antimicrobial resistance: development of an ‘antibiotic footprint calculator’

Prapharsavat R. et al, (2023), Journal of Antimicrobial Chemotherapy, 78, 1317 - 1321

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open- label, randomised, controlled adaptive platform trial

Luvira V. et al, (2023)

Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)

Schilling WHK. et al, (2023), eLife, 12

Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study

Perrone C. et al, (2022), Wellcome Open Research, 6, 216 - 216

Load More